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Abstract
Osteochondrosis (OC) is a developmental disease in horses with a significant impact on the horse’s welfare and
performance. Previously, differentially expressed genes in leukocytes of OC-affected have been identified and were
differentially expressed in horses of different ages when compared to their age-matched controls.As the time course
of the development of OC lesions seems to be joint dependent,the aim of this study is to compare in young OC-
affected horses (between 8 to 12 months), the different expression of selected genes depending the joints
involved.The expression of OC-related genes were analysed by rt-PCR and subsequent statistical analysis (ΔΔCT)
in the leukocytes of 30 Belgian Warmblood horses aged between 8 to 12 months divided in groups depending the
affected joints (fetlock, hock and stifle).In the three groups, expression of ApoB-3G, MGAT4A, B4GALT6 and
PRKCG genes were significantly higher in the OC-affected foals compared to the healthy foals. Based on the
profiles of expression ofApoB-3G, Dsh1/Dvl1, Foxl1, Hp, ISG15, Mark2, PPR2A, RUSC2 and WASH1 genes,the
localization of the disease can be determined: expression levels of ApoB3G, WASH1 and FOXl1 to identify fetlock,
ApoB3G, PPR2A to identify OC-development in the hock and ApoB3G, Dsh1/Dvl1, WASH1, PPP2R1A and Mark2
geneto identify OC-development in the stifle. However at this moment, the rt-PCR analysis of the identified genes as
biomarkers gives only diagnostic information. For the future, the profile of expression of these genes could give also
some predictive information on the evolution of the disease such as remission or permanent OC-lesions.
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Introduction
The developmental orthopaedic disease osteochondrosis (OC)
affects growing horses and severely compromise their athletic careers
[1-4]. OC is considered a major cause of considerable economic losses
in the horse breeding industry [5,6] with reported incidences ranging
from 10% to 44% [6-9].
A common mechanism of dyschondroplasia may affect different
joints, particularly the metacarpo- and metatarso-phalangeal joints,
the lateral ridge of the talus or the tibial cochlea in the tibio-tarsal
joint, and the lateral ridge of the trochlea in femoro-patellar joints.
The disease appears to be multifactorial in origin, including skeletal
growth rates, nutrition, endocrinologic factors, and exercise of the
horse, biomechanics, and genetic effects [10]. High energy diet is
known to induce OC lesions in foals [11,12]. Furthermore, it appears
that mares fed with concentrates during gestation are more likely to
produce foals that are subsequently affected by OC compared with
other mares [13].
Several studies focused on the identification of target genes and
biomarkers. Studies on signal transduction and gene expression in
equine cartilage metabolism tried to elucidate the underlying
molecular mechanisms of OC [12,14] and to identify candidate genes
[15,16].
In a previous study, we analyzed the transcript profile of leukocytes
from horses affected with OC using the high throughput sequencing
method digital gene expression analysis (DGE) [17]. Metabolic
pathways analysis showed an obvious dysregulation of several
signaling pathways related to cartilage formation and cartilage repair
like e.g. Wnt-, Indian hedgehog- and TGF-beta signaling pathways.
Other genes regulated may play a role in high carbohydrate diet,
abnormal insulin metabolism or inflammation [17]. Based on this
DGE analysis, a more recent study has demonstrated that OC-related
genes are differentially expressed in horses of different ages when
compared to their age-matched controls. Some of the genes are
implicated in cell signaling and differentiation as well as carbohydrate
and lipid metabolism and inflammation (data submitted).
However, the time course of the development of OC lesions seems
to be joint dependent. It has been shown that OC lesions appear
rapidly after birth but most of these lesions regress in the following
months up to the age of 1 year. OC lesions develop in the hock joint in
the first month of life. Followed by a period of regression they seem to
be stationary after the fifth month of life. In the stifle, this process is
more delayed and most OC lesions develop around the fifth month of
age, thereafter they can decrease to become stationary at the age of
eleven months [18]. Thus, the profile of expression of genes could be
different depending to the localisation or the stage of the disease. The
aim of this study is to compare in young OC-affected horses (between
8 to 12 months), the different expression of selected genes depending
the joints involved.
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Material and Methods
Animal
30 Belgian Warmblood horses with osteochondrosis and 11 Belgian
Warmblood horses free of osteochondrosis were included in this
study. All horses were between 8 to 12 months old.
The horses were checked for osteochondrosis-specific lesions using
radiography. All horses were sedated for the radiographic examination
using detomidine (0.01 mg/kg IV) alone or combined with
butorphanol (0.02 mg/kg IV). The following views were taken: dorso
60° proximo-palmarodistal oblique and weight bearing lateromedial
views of the front feet, lateromedial views of the 4 fetlocks,
lateromedial and plantarolateral-dorsomedial oblique views of the
hocks and a lateromedial view of the stifles. Horses with palmar or
plantar fragmentations of the proximal phalanx were not included in
this study. Horses were diagnosed on the basis of characteristic lesions
of abnormal endochondral ossification located in the fetlock (n=12),
hock (n=6), and stifle joints (n=12). Horses with multiple lesions were
excluded from the study. Eleven horses without any evidence of
osteochondrosis-specific lesions were analyzed as a control group.
Rt-PCR analysis
Blood was collected from each horse with PAXgene blood RNA
tubes (BD Diagnostics, Le Pont de Claix, France) and frozen at -80°C
for later analysis. Total RNA was extracted from total blood (2.5ml)
using the PAXgene blood RNA kit (Qiagen, Courtaboeuf, France). The
integrity of total RNA extracted using the PAXgene method was
checked by capillary electrophoresis analysis on Agilent BioAnalyser
2100 (Agilent, Palo Alto, CA, USA). RNA quantity was measured
using a spectrophotometer NanoDrop ND-1000 (Thermo Scientific,
Les Ulis, France).
cDNA were synthesized using ~300ng of total RNA and performed,
using the VILO reverse transcription Kit, according to the
manufacturer’s protocol (Invitrogen, CergyPontoise, France).
Pre-amplification was performed with a 22 pooled (final 0.2X of
each) SYBR Green assay. After pre-amplification PCR, the product
was treated with 4U of Exonuclease I (NEB) then diluted 1:5 with 1X
TE Buffer and stored in -80°C until needed. qPCR was carried out
using the 96.96 dynamic array (Fluidigm Corporation, CA, USA)
following the manufacturer's protocol. Specifically, a 5 μl sample
mixture was prepared for each sample containing 1 × TaqMan Gene
Expression Master Mix, 1 × GE Sample Loading Reagent (Fluidigm
PN 85000746), 1 x EvaGreen (Interchim) and each of diluted pre-
amplified cDNA. 5 μl of Assay mix was prepared with 1 × each of
SYBR Green assay and 1 × Assay Loading Reagent (Fluidigm PN
85000736). An IFC controller was used to prime the fluidics array
(chip) with control line fluid and then with samples and assay mixes in
the appropriate inlets. After loading, the chip was placed in the
BioMark Instrument for a first step of thermal mixing at 50°C for 2
min, 70°C for 30 min and 25°C for 10 min, then UNG & HotStart step
at 50°C for 2 min followed by 95°C for 2 min. The PCR was performed
by 35 cycles at 95°C for 15 sec and 60°C for 1 min. Finally, melting
curve was performed by increasing temperature from 60°C to 95°C.
The data was analyzed with Real-Time PCR Analysis Software in the
BIOMARK instrument (Fluidigm Corporation, CA, USA).
Gene symbol Name Trancrypt ID (ensembl or Genbank)
ADAMTLS4 ADAMTS-likeprotein 4 precursor ENSECAT00000020422
ApoB Apolipoprotein B ENST00000233242
ApoB3G similar to ApoBmRNAediting enzyme catalytic polypeptide-like 3G XM_001916520
B4GALT6 Beta-1,4-galactosyltransferase 6 ENSECAT00000018745
BMP5 Bonemorphogeneticprotein 5 ENSECAG00000007138
CLK1 Dual specificityprotein kinase ENSECAT00000016444
CRKL Crk-likeprotein ENSECAT00000018670
CSNK1E Casein kinase I isoform epsilon ENSECAT00000023450
CtBP1 C-terminal-binding protein 1 ENSECAT00000016987
CUL5 Cullin-5 (Vasopressin-activated calcium-mobilizingreceptor) ENSECAT00000026414
DVL1 Segment polarityproteindishevelledhomolog DVL-1 ENST00000378891
DVL3 Segment polarityprotein disheveled homolog DVL-3 ENSECAT00000009739
FOXL1 Forkhead box L1 ENST00000320241
FOXO1 Forkhead box O1 ENST00000379561
FZD1 Frizzledfamilyreceptor 1 ENSECAG00000001326
GRB2 growth factor receptor-boundprotein 2 ENSECAG00000006524
GSK3B glycogen synthase kinase 3 beta ENSECAT00000026913
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Hp Haptoglobin XM_001497810
IFIH1 Interferoninducedwithhelicase C domain ENST00000263642
IKBKB Inhibitor of nuclear factor kappa-B kinase subunit beta ENSECAT00000005219
ISG15 Interferon-inducedproteinprecursor, ENSECAT00000001183
MGAT4A Mannosylglycoproteinacetylglucosaminyltransferase ENSECAG00000015468
MHCI MHC class I heavychain ENSECAT00000021999
MHCIIa Similar to MHC class II antigen DQ alpha chain ENSECAT00000022398
MMP1 Interstitialcollagenaseprecursor(Matrix metalloproteinase-1) ENSECAT00000025715
OAS3 2'-5'-oligoadenylate synthetase 3 ENST00000549918
PPP1CB protein phosphatase 1, catalyticsubunit, beta isoform ENSECAG00000009359
PPR2A protein phosphatase 2, regulatorysubunit A, alpha isoform ENSECAT00000019754
PRKCG protein kinase C, gamma ENSECAT00000020980
PYGL phosphorylase, glycogen, liver ENSECAT00000013037
RUSC2 Iporin (Interactingprotein of Rab1) (RUN and SH3 domain-containingprotein
2)
ENSECAT00000026463
SECTM1 Secreted and transmembraneprotein 1 precursor ENSECAT00000006039
SMAD5 SMAD familymember 5 ENSECAG00000000815
TBC1D9 TBC1 domainfamilymember 9B ENSECAT00000018936
WASH1 WAS proteinfamilyhomolog 1 XM_001493185.2
Table 1: 35 selected genes based on the study of Serteyn et al. [17]: a low p-value (inferior to 0.1%), fold induction superior to 5, quality of
annotation (existence of a lot of predicted mRNA in the horse genome), a mix of up- and down-regulated genes involved in known signaling
pathways
In the previous study, we have identified 2,553 genes significantlyup
or down regulated between the OC-group and the control group
[17].For the present study, we chosen35genes following different
criteria: a low p-value (inferior to 0.1%), fold induction superior to 5,
quality of annotation (existence of a lot of predicted mRNA in the
horse genome), a mix of up- and down-regulated genes involved in
known signalling pathways (Table 1).Four control genes: WARS
(Tryptophanyl-tRNAsynthetase), RIGE (Retinoic acid-induced gene E
protein), B2M(Beta-2-microglobulin) and TUBB2C (Tubulin, beta
2C), referred to as housekeeping genes, were used to normalise mRNA
levels between different samples.Real-time PCR analysis was
performed for each of the markers and housekeeping genes, for each
measured marker or housekeeping gene, a cycle threshold value (Ct-
value) was obtained.
The expression levels of the markers in horses affected by
osteochondrosis and in the control group were compared by
calculating 2-ΔΔCt (SchmittgenetLivatk, 2008). Here, ΔCt=CtMarker -
CtHousekeeping gene, and ΔΔCt=ΔCtSubject - ΔCtControl group.
Statistical analysis
For comparison of the quantitative variables the normality was
tested using Shapiro-Wilk, the normality was rejected and a non-
parametrical method was used to assert of significant differential gene
expression. A Kruskall-Wallis test and a Nemenyi test were used to
identify the difference. All statistical tests were performed on the Delta
Cycle Threshold (dCt) matrix and using R software v2.14.0. All tests
performed were performed with 5% type I (alpha) error.
Results
12 genes amongst the 35 genes studied showed a significant
difference of expression between the OC-affected foals and the healthy
foals are reported in Table 2.
 Fetlock Hock Stifle
ApoB-3G 5.33 ± 1.95 5.76 ± 1.68 5.50 ± 2.08
MGAT4A 2.04 ± 0.14 2.14 ± 0.23 1.82 ± 0.12
B4GALT6 2.21 ± 0.24 2.36 ± 0.28 2.21 ± 0.18
PRKCG 1.59 ± 0.11 1.88 ± 0.09 1.94 ± 0.13
Dsh1/dvl1 0.73 ± 0.10 0.74 ± 0.12 0.34 ± 0.06
Foxl1 0.49 ± 0.10 1.04 ± 0.20 0.48 ± 0.14
Hp 0.77 ± 0.23 0.01 ± 0.01 0.63 ± 0.15
ISG15 0.88 ± 0.29 0.21 ± 0.07 0.23 ± 0.12
Mark2 0.73 ± 0.13 0.78 ± 0.14 0.46 ± 0.08
Citation: Serteyn D, Piquemal D, Mendoza L, Caudron I, Noguier F, et al. (2014) Osteochondrosis-Related Gene Expression in Equine
Leukocytes Differs among Affected Joints in Foals. J Mol Biomark Diagn 5: 189. doi:10.4172/2155-9929.1000189
Page 3 of 6
J Mol Biomark Diagn
ISSN:2155-9929 JMBD, an open access Journal Volume 5 • Issue 5 • 1000189
PPR2A 1.16 ± 0.17 0.57 ± 0.12 0.19 ± 0.04
RUSC2 0.84 ± 0.10 0.31 ± 0.05 0.25 ± 0.04
WASH1 1.414 ± 0.18 0.77 ± 0.08 0.46 ± 0.06
Table 2: Significant (p<0.05) fold induction differences (mean values ±
standard deviations) between the OC-affected foals and the healthy
foals
Whatever the joint affected, expression of ApoB-3G, MGAT4A,
B4GALT6 and PRKCG genes were significantly higher in the OC-
affected foals compared to the healthy foals. Fold induction of these
genes are illustrated in Figure 1.
Figure 1: 4 genes amongst the 35 studied showed a significant
(P<0.05) fold induction in the OC-affected foals wathever the joint
affected compared to the healthy horses. Results are expressed as
mean (± standard deviation) values. (reference values=1)
Figure 2:8 genes amongst the 35 studied showed significant
(p<0.05) different profiles of expression related to the affected joint.
Results are expressed as mean (± standard deviation) values
Furthermore,the data show that the expression pattern of 8 genes
(Dsh1/dvl1, Foxl1, HP, ISG15, Mark2, PPR2A, RUSC2, WASH1) show
significant variations compared to the healthy foals but also between
the affected joints as illustrated in Figure 2.
Dsh1/Dlv1 was found underexpressed in blood samples of horses
affected in the three joints, but especially in the stifle joint. The
expression of Foxl1 is normal in horse affected in the hock joint, but
this gene is found underexpressed in horses affected in the fetlock joint
and the stifle joint. Hp is found underexpressed in fetlock joint and
stifle joint affected horses, and is barely detectable in the hock joint
affected horses. The expression of ISG15 is unchanged in fetlock joint-
affected horses, but this gene is found underexpressed in hock joint
and stifle joint-affected horses. The expression profile of Mark2 is
basically the same than these of Dsh1/dvl1. PPR2A share the same
expression profile. They are overexpressed in fetlock joint-affected
horses, but they were found underexpressed in hock joint and stifle
joint affected horses. RUSC2 is slightly underexpressed in fetlock
joint-affected horses, and is much more underexpressed in hock joint
and stifle joint-affected horses. Finally, Wash1 is found overexpressed
in blood samples of fetlock joint-affected horses, but was found
underexpressed in hock joint and stifle joint-affected horses.
Based on the profiles of expression of ApoB-3G, Dsh1/Dvl1, Foxl1,
Hp, ISG15, Mark2, PPR2A, RUSC2 and WASH1 genes,the localization
of the disease can be determined: expression levels of ApoB-3G,
WASH1 and FOXl1 to identify fetlock (Figure 3a), ApoB3G, Hp,
PPR2A to identify OC-development in the hock (Figure 3b) and
ApoB-3G, Dsh1/Dvl1, Mark2, PPP2R1A and WASH1 gene to identify
OC-development in the stifle (Figure 3c).
Discussion
In this study, we identified localization-dependent differentially
expressed genes in leukocytes of OC-affected horses. Gene expression
analysis offers the opportunity to identify a particular environmental
effect on biological pathways as well as how this regulation is
potentially altered in the development of certain diseases [19].
Recently, peripheral blood leukocytes were suggested as a surrogate
tissue to substitute for traditional tissue specimens that are not easily
accessible [20,21]. The suitability of leukocytes for gene profiling is
related to their active metabolism [22] and accessibility by simple
venipuncture [21,23], which may allow a repeated time-series analysis
of changes in gene expression in response to changing environmental
or disease factors. Previous studies have demonstrated the potential of
using gene expression levels of peripheral blood leukocytes as a novel
biomarker of nutritional interventions [24], to predict weight loss
regain in obese subjects [25,26], and to predict the inflammatory
response to functional foods [27].
Amongst the environmental parameters influencing the onset of
OC, a high energy diet is known to induce OC lesions in foals [11,12].
These observations were illustrated recently by Vanderheyden et al.
[13]. Our previous study showed that MGAT4 gene remains
overexpressed in OC-affected foals whatever the age [data submitted).
It was demonstrated that transient hyperglycemia causes in an animal
model persistent epigenetic changes and altered gene expression
during subsequent normoglycemia. This mechanism implicates a
mitochondrial pathway with a high superoxide anion production [28].
Furthermore, TBC1D9 (GTPase activator activity, calcium) genes are
up regulated in the OC-affected foals. This gene may act as a GTPase-
activating protein for Rab family proteins and is also related to the
insulin pathway and the glucose transporter 4. Recently, abnormal
mitochondria and endoplasmic reticulum were observed in the deep
zone of OC cartilage [29]. The mitochondrial dysfunction could be
partially explained by the altered Wnt signaling pathway observed in
the OC-affected horses because this pathway is known as a key
regulator of mitochondrial function [17,30]. Furthermore, Power et al.
[31] demonstrated by immunohistochemistry that sclerostin, a major
inhibitor peptide of the canonical Wnt pathway signaling was
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increased in naturally occurring lesions of equine osteochondrosis.
Our study is limited to the mRNA expression without information on
the proteins transcription.
Figure 3: Variations of the fold induction of specific genes for each
joint. The arbitrary value of 1 is given to the normal horse values.
Bar error indicates the standard deviation values of the fold
induction.a: Set of genes to the “fetlock” localization in young
horse. Fold induction of gene expression in the condition OCD
“fetlock” versus normal horses using the 2 E-(ddCT). b: Set of genes
to “hock” localization in young horse. Fold induction of gene
expression in the condition OCD “hock” versus normal horses
using the 2 E-(ddCT). c:Set of predictive genes to “stifle”
localization in young horse. Fold induction of gene expression in
the condition OCD “stifle” versus normal horses using the 2 E-
(ddCT)
Our results showed clearly that in young horses (before one
year)the profile expression of the selected genes was different in
relation to the localization of the disease. We can assume that, at the
time of the blood samples, the OC-affected foals were at different
stages of the disease depending the affected joint. The time course of
the development of OC lesions seems to be joint dependent.These
observations confirm the results observed by the follow-up reported by
van Weeren et al. [18]. For example, at the opposite to the fetlock and
hock lesions, most OC lesions in the stifles develop around the fifth
month of age, thereafter they can decrease to become stationary at the
age of eleven months.
Based on these preliminary results, we can determine, by a Rt-PCR
analysis of the selected genes identified as possible biomarkers, if the
foal is affected by OC and which joint is concerned by the disease.
However, the main limitations of this “case-contol study” is the few
number of foals and the fact that the rt-PCR analysis of the identified
genes as biomarkers give only diagnostic information. We plan to
perform a “cohort study” on a more large population. For the future,
the profile of expression of these genes could give also some predictive
information on the evolution of the disease such as remission or
permanent OC-lesions.
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